Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Abstract Number: PB0608

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – MOTIVATE (www.motivate-study.com)

C. Escuriola Ettingshausen¹, R.F. Sidonio, Jr.²

Abstract Number: PB0627

PRactical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment with Nuwiq^®, octanate^® or wilate^® – The Protect-NOW Study

J. Oldenburg¹, P.M. Vera², S. Halimeh³, R. Klamroth⁴, S. Lowndes⁵, M. Jansen⁶

Abstract Number: PB0594

2 Years ofPprophylaxis with rFVIII-Fc in Haemophilia in a Portuguese Haemophilia Center: Did Doctors and Patients See a Change?

S. Campaniço¹, F. Rodrigues¹, A. Pereira¹, J. Amorim¹, C. Correia¹, L. Parusnikova¹, C. Catarino¹

Abstract Number: PB0624

A Bleed Suppression Efficacy of Emicizumab in Patients with Hemophilia A whose Therapies Switched from Conventional Prophylaxis

T. Fujii¹, N. Yamasaki¹, T. Inoue¹, T. Fujii¹

Abstract Number: PB0640

A Prospective Cohort Study on Disabilities in Patients with Haemophilia Using Orthopaedic Scores

M. Bajracharya¹, B.S. Poudyal¹, S. Marahatta¹, S. Rayamajhi¹, V. Prajapati¹, C.D.K. Mahato¹

Abstract Number: PB0586

A Qualitative Study on the Experiences of Hemophilia Carriers before, during and after Pregnancy

M.C. Punt¹, L. Teela², K. Fischer¹, K.W.M. Bloemenkamp³, A.T. Lely³, M.H.E. Driessens⁴, L. Pekel⁴, L. Haverman², K.P.M. van Galen¹.

Abstract Number: PB0533

A single center study of bone mineral density in adult patients with severe Haemophilia A and correlation with markers of bone metabolism

H. Ivanova¹, Z. Grudeva-Popova¹, T. Deneva¹, N. Mateva^2,2

Abstract Number: PB0628

A Study of Psychosocial Issues for Mothers of Children with Hemophilia

A. Nakao¹, J. Yamanouchi¹

Abstract Number: PB0574

Adherence to Prophylaxis and Recording of Home-treatment Following a Switch to Extended Half-life Clotting Factor Concentrate

M. O'Donovan^1,2, C. Bergine¹, N. Larkin¹, E. Singleton¹, J. Benson¹, F. McGroarty¹, L. Jeffrey³, R. Bird¹, C. Buckley¹, K. Ryan¹, J.S. O'Donnell¹, N.M. O'Connell^1,2

Abstract Number: PB0530

Adoption of Emicizumab for Hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders Survey

E. Krumb¹, K. Fijnvandraat², M. Makris³, F. Peyvandi^4,5, A. Ryan⁶, A. Athanasopoulos⁶, C. Hermans¹

Abstract Number: PB0623

AKATSUKI Study: A Prospective, Multicenter, Phase IV Study to Evaluate the Safety of Emicizumab Under and Immediately After Immune Tolerance Induction (ITI) Therapy in Persons with Congenital Hemophilia A (PwHA) with Factor (F) VIII Inhibitors

T. Matsushita¹, N. Suzuki¹, A. Nagao², C. Nagae³, H. Yamaguchi-Suita⁴, Y. Kyogoku⁴, A. Ioka⁴, K. Nogami⁵

Abstract Number: PO140

Analysis of Hospitalization Factors of Hemophilia: 12 Years of Experience in a Single Center

C. Qu¹, F. Xue¹, W. Liu¹, L. Chen¹, L. Zhang¹, R. Yang¹

Abstract Number: PB0622

AOZORA Study: Long-Term Safety and Joint Health in Pediatric Patients with Hemophilia A without FVIII Inhibitors Receiving Emicizumab – Protocol for a Multicenter, Open-label, Phase IV Clinical Study

M. Shima¹, H. Takedani², K. Kitsukawa³, M. Taki⁴, A. Ishiguro⁵, A. Nagao⁶, H. Yamaguchi-Suita⁷, Y. Kyogoku⁷, S. Yoshida⁷, K. Nogami¹.

Abstract Number: PB0528

Assessment of the Bleeding Phenotype in Patients with Non-severe Hemophilia According to the ISTH Bleeding Assessment Tool (BAT)

F. Kloosterman¹, A. Zwagemaker¹, S.C. Gouw^1,2, C.N. Bagot³, P. Brons⁴, M. Cnossen⁵, P. Collins⁶, S. Jackson⁷, K. Meijer⁸, M.J.H.A. Kruip⁹, F.W.G. Leebeek⁹, B. Laros-van Gorkom¹⁰, C. Male¹¹, I. Pabinger¹², S. Shapiro¹³, M. Coppens¹⁴, J.G. van der Bom¹⁵, K. Fijnvandraat^1,16, DYNAMO Study Group

Abstract Number: PB0592

Assessment of Thrombin Generation on Severe Haemophilia A Patients in the Clinical Laboratory

J. Mullins¹, D. White¹, S. Cox-Morton¹, A. Marin², M. Gironella², F. Bosch², S. Franco², A. Tosetto³, S. Mac Donald¹

Abstract Number: PB0616

Association of Individual Pharmacokinetics-guided Regimen in Hemophilia A Patients and FVIII Consumption: A Single-center Study

Q. Hong¹, C. Shu Qin¹, Z. Wen Jing², H. Xiao Hua³, C. Yong Fang¹, Y. Yu Hua¹, X. Xing Yi⁴

Abstract Number: PB0512

Association of Physical Activity with Bleeding Frequency in Children with Hemophilia A: A CHESS PAEDs Study Analysis

R. Ofori-Asenso¹, F. Nissen², M. Silkey², T. Xu², H. Yamaguchi-Suita³, D. Nosaka³, M. Aizenas², O. Meier², T. Burke^4,5, J. O'Hara^4,5

Abstract Number: PB0552

B-MORE, Baseline Analysis from a 24-month Prospective, Non-interventional, Multicentre Study on Real-world Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B

G. Castaman¹, S. Ranta², D. Allsup³, H. Glosli⁴, M. Saleh⁵, Å. Carlsheimer⁶, A. Francke⁶, E. Santagostino⁷

Abstract Number: PB0630

Benefits of Prophylactic Emicizumab in Enhancing Immune Tolerance Induction in a Hemophiliac Boy with Very High Inhibitor Titer

N. Sirachainan¹, A. Chuansumrit¹, S. Parapakpenjune², P. Wongwerawattanakoon³, S. Lertthammakiat⁴, P. Kadegasem¹, W. Sasanakul¹

Abstract Number: PB0604

Can Plasminogen Activator Inhibitor 1 and Thrombin Activitable Fibrinolysis Inhibitor Explain Bleeding Phenotype in Hemophilia A?

S. Elhefnawy¹, M. Abd Elrehim², M. Elhawy².